This is a knockout-validated antibody summary, based on two publications "SRT1720 induces lysosomal-dependent cell death of breast cancer cells" [2] and "SIRT1-mediated downregulation of p27Kip1 is essential for overcoming contact inhibition of Kaposi" [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Mouse monoclonal

Company: Cell Signaling Technology

Antibody: SIRT1

Catalog number: 8469 (1F3)

Summary: Mouse monoclonal antibody raised against a recombinant protein corresponding to the C-terminal region of human SIRT1. Supplier recommended for WB, IP and IF. Reacts with human, mouse, rat and monkey SIRT1.

Western blot

Human MDA-MB-231 breast cancer cell lines treated with control or SIRT1 shRNA.

PBS containing 4% milk powder.

Anti-SIRT1 antibody diluted in PBS containing 1% milk powder and 0.1% Tween 20.

HRP-conjugated anti-mouse IgG (GE Healthcare).

ECL reagent (Denville Scientific).

[enlarge]

Figure 1. Western-blotting analysis of SIRT1 in the wild-type (WT) and SIRT1 knockout (KO) cultures of MM and KMM cells using β-actin as a loading control. From [1].

See Figure 1 from [2].

Western blot (Figure 1).

Primary rat embryonic metanephric mesenchymal precursor (MM) cells and KSHV-transformed MM cells (KMM).

Luminiata Crescendo Western HRP substrate (Cat.# WBLUR0500, EMD Millipore, San Diego, CA).

KO validation by IF is presumably with the same antibody (Fig S1).

The same clone (1F3) is sold as Novus Biologicals NBP1-51641; OriGene TA336801; LifeSpan Biosciences LS-C169237, LS-C359279; Abnova MAB10318; Invitrogen MA5-15677; GeneTex GTX82793; MyBioSource MBS850730; Cell Signaling Technology 8469.